Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM

Boston-based ZIOPHARM Oncology presented data today at the 2020 American Society of Clinical Oncology annual meeting from its Phase I monotherapy study for Controlled IL-12, Ad-RTS-hIL-12 plus veledimex (Ad+V). In addition, it provided updated clinical data from two Phase I sub-studies of Ad+V – a monotherapy expansion study and a combination study with a PD-1 inhibitor – for the treatment of adult recurrent or progressive glioblastoma multiforme (rGBM).